Videos

A 54-Year-Old Woman With Stage 2 HER2+ Breast Cancer

Carrie L. Langstraat, MD, discusses how para-aortic lymph node metastases impact survival outcomes in patients with endometrial cancers.

Jonathan C. Trent, MD, PhD, discusses some of the recent immunotherapeutic advances in the treatment landscape for patients with sarcoma, particularly with immune checkpoint inhibitors.

Brad Kahl, MD, discusses the treatment options for patients with indolent lymphomas who are relapsed/refractory.

A 62-Year-Old Woman With Metastatic BRAF V600E-Mutated NSCLC

Angeles Alvarez Secord, MD, discusses the key takeaways on the role of PARP inhibitors in ovarian cancer, based on data presented for 3 PARP inhibitors, olaparib, rucaparib, and niraparib.

Eugene B. Cone, MD, discusses the strategies for treating patients with prostate cancer who develop adverse events, such as cardiac events and immune-related events.

A 63-Year-Old Woman With Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

A 75-Year-Old Man With Metastatic Castrate-Resistant Prostate Cancer

Ruben Mesa, MD, discusses the role of ruxolitinib and fedratinib, first-generation JAK inhibitors, as treatment of patients with myelofibrosis.

Bradley McGregor, MD, discusses a trial investigating atezolizumab and bevacizumab in patients with metastatic renal cell carcinoma and variant histologies and/or sarcomatoid features.